FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia

On July 11, 2017, the Food and Drug Administration granted approval for blinatumomab for the treatment of relapsed or refractory (R/R) precursor B‐cell acute lymphoblastic leukemia (ALL). Blinatumomab is a bispecific CD19‐directed CD3 T‐cell engager. The basis for the approval included results from...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Pulte, E. Dianne, Vallejo, Jonathon, Przepiorka, Donna, Nie, Lei, Farrell, Ann T., Goldberg, Kirsten B., McKee, Amy E., Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2018
Assuntos:
Regulatory Issues: FDA
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291336/
https://ncbi.nlm.nih.gov/pubmed/30018129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0179
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares